The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through the Kansas City Clinical Oncology Program (KCCOP), Sarah Cannon Research Institute, and various pharmaceutical and CRO partners.

AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

AML 43: Randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without glasdegib (pf-04449913) or azacitidine (aza) with or without glasdegib in patients with previously untreated acute myeloid leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

CLL 44: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 122: A phase 3, randomized, double blind, placebo controlled, multicenter study of BR alone versus in combination with Acalabrutinib (ACP-196) in subjects with previously untreated mantle cell Lymphoma, radiologically measurable lymphadenopathy or extranodal lymphoid malignancy. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

LYM 126: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

LYM 131: Phase 3 Study of Ibruinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma (MCL). PI: Suman Kambhampati, MD
Facility: Research Medical Center

LYM 132: A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kä Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 135: A phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with rituximab and chp (r-chp) versus rituximab and chop (r-chop) in previously untreated patients with diffuse large b-cell lymphoma. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MDS 21: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM 74: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

MM 99: A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM). PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

BRE 274: A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 296: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer. PI: Stephanie Graff, MD
Facility: Menorah Medical Center, Research Medical Center

BRE 298: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 302: Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 303: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

  :  
Facility:  

GI 201 - INN: A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line Treatment of Patients with Metastatic Gastroesophageal Cancer. PI: Jaswinder Singh, MD
Facility: Research Medical Center

GI 247: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer. PI: Jaswinder Singh, MD
Facility: Menorah Medical Center, Research Medical Center

GI 268: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locallyadvanced pancreatic adenocarcinoma. PI: Jaswinder Singh, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 118: An Open-Label, Non-randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY). PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 135: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemo-therapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 137: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 142: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 144: A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced or Metastatic Papillary Renal Cell Carcinoma. PI: Peter Van Veldhuizen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 147: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind study of Atezolizumab (Anti-PD-L1 antibody) as adjuvant therapy in patients with PD-L1 selected renal cell carcinoma at intermediate to high risk of developing metastasis following nephrectomy. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 148: A phase III, randomized, double-blind, placebo-controlled, multicenter trial testing ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/ prednisolone in patients with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer with pten-loss (pten diagnostic positive) tumors. PI: Peter Van Veldhuizen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 149: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma. PI: Peter Van Veldhuizen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 150: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC). PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 161: An Open-Label Phase 1/2A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer. PI: Peter Van Veldhuizen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MULTI 26: A Phase II, Open-label, multicenter, multicohort study to investigate the efficacy and safety of Cobimetinib plus Atezolizumab in patient with solid tumors. PI: Peter Van Veldhuizen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN 78: A phase 2, single-arm, open-label study to evaluate the safety and efficacy of niraparib combined with bevacizumab as maintenance treatment In patients with advanced ovarian cancer, fallopian tube Cancer, or primary peritoneal cancer following front-line platinum-based chemotherapy with bevacizumab. PI: Kristopher LyBarger, DO
Facility: Centerpoint Medical Center, Research Medical Center

GYN 79: Protocol I4D-MC-JTJN A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer. PI: Kristopher LyBarger, DO
Facility: Centerpoint Medical Center, Research Medical Center

GYN 80: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer. PI: Kristopher LyBarger, DO
Facility: Centerpoint Medical Center, Research Medical Center

CNS 24: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, combined with Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma. PI: Amandeep Kalra, MD
Facility: Research Medical Center

CNS 25: A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradation and Adjuvant Temozolomide Chemotherapy. PI: Amandeep Kalra, MD
Facility: Menorah Medical Center, Research Medical Center

REFMAL 365: A Phase Ib Study evaluating the c-Met Inhibitor INC280 in Combination with Bevacizumab in Glioblastoma Multiforme (GBM), Patients. PI: Amandeep Kalra, MD
Facility: Menorah Medical Center, Research Medical Center

LUN 349: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU). PI: Joseph Stilwill, MD
Facility: Menorah Medical Center, Research Medical Center

LUN 350: A Phase 3 Randomized, Open Label Efficacy and Safety Study of Lorlatinib Monotherapy vs Crizotinib Monotherapy in 1st Line Treatment of ALK-positive NSCLC. PI: Joseph Stilwill, MD
Facility: Menorah Medical Center, Research Medical Center

LUN 380: A Phase II, Randomized, Blinded, Placebo-Controlled Study of MTIG7192A, an Anti-Tigit Antibody, in Combination with Atezolizumab in Chemotherapy-Naïve Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. PI: Joseph Stilwill, MD
Facility: Menorah Medical Center, Research Medical Center

LUN 385: A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients With Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center